A pharmacokinetic study to determine the drug interaction between valproate and propranolol

Pharmacotherapy

Volumn 16, Issue 6 I, 1996, Pages 1059-1062

  Nemire, Ruth E ^a   Toledo, Cynthia A ^b   Ramsay, R Eugene ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROPRANOLOL; VALPROATE SEMISODIUM;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; EPILEPSY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREMOR;

ADULT; ANTICONVULSANTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PROPRANOLOL; SEIZURES; VALPROIC ACID;

EID: 0029806753     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Dreifuss FE, Langer DH. Side effects of valproate. Am J Med (suppl 1A) 1988;84:34-41.
2. Wilder BJ, Ramsay RE, Murphy JV. Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures. Neurology 1983;22:1474-6.
3. McAllister RG, Markesbery WR, Ware RW, Howell SM. Suppression of essential tremor by propranolol: correlation of effect with drug plasma levels and intensity of beta adrenergic blockade. Ann Neurol 1977;1:160-166.
4. Herranz JL, Arteaga R, Armijo JA. Side effects of sodium valproate in monotherapy controlled by plasma levels: a study in pediatric patients. Epilepsia 1982;23:203-14.
5. Collaborative Study Group: Bourgeois, B. et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia (suppl 2) 1987;28:S8-11.
6. Karas BJ., Wilder BJ., Hammond EJ, et al. Treatment of valproate tremors. Neurology 1983;33:1380-2.
7. Koller WC, Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 1989;39:1587-8.
8. Nitsche V, Mascher H. The pharmacokinetics of valproic acid after oral and parenteral administration in healthy volunteers. Epilepsia 1982;23:153-62.
9. Perucca E, Gatti G, Figo GM, Crema A. Pharmacokinetics of valproic acid after oral and intravenous administration. Br J Clin Pharmacol 1978;5:313-18.
10. Ochs HR, Greenblatt DJ, Verburg-Ochs B. Propranolol interactions with diazepam, lorazepam and alprazolam. Clin Pharmacol Ther 1984;36:451-55.
11. Conrad KA, Nyman DW. Effects of metoprolol and propranolol on theophylline elimination. Clin Pharmacol Ther 1980;28:463-7.
12. Greenblatt DJ, Franke K, Huffman DH. Impairment of antipyrine clearance in humans by propranolol. Circulation 1978;57:1161-4.
13. Otton SV, Gillam EM, Lennard MS, Tucker GT, Woods HF. Propranolol oxidation by human liver microsomes - the use of cumene hyperoxide to probe isoenzyme specificity and regio-and stereoselectivity. Br J Clin Pharmacol 1990;30:751-60.
14. Ochs HR, Carstens G, Greenblatt DJ. Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med 1980;303:373-7.
15. Turnbull DM, Rawlins MD, Weightman D, Chadwick D. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. J Neur Neurosurg Psych 1982;45:55-9.
16. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989;45:72-9.
17. Guttendorf RJ, Wedlund PJ. Genetic aspects of drug disposition and therapeutics. J Clin Pharmacol 1992;32: 107-17.